Search Results for: cronos
Cronos Group Appoints James Holm as Chief Financial Officer
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid…
Cronos Group Reports 2022 Third Quarter Results
Reported consolidated net revenue increased 3% year-over-year to $20.9 million; on a constant currency basis,…
Cronos Group Reports 2022 Second Quarter Results
Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net…
Cronos Group Inc. to Hold 2022 First Quarter Earnings Conference Call on May 10, 2022
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2022…
Cronos Group Inc. to Hold 2022 First Quarter Earnings Conference Call on May 10, 2022
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2022…
Cronos Group Reports 2021 Fourth Quarter and Full-Year Results
Consolidated net revenue increased 59% in Full Year 2021 compared to Full Year 2020 Announces…
Cronos Group Inc. to Hold 2021 Fourth Quarter and Full-Year Earnings Conference Call on March 1, 2022
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its…
Cronos Group Reports 2021 Third Quarter Results
Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment…
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”), the Canadian company defining the future of cannabinoids worldwide,…
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ | TSX: ACB) (“Aurora”), the Canadian company defining the future of…
Recent Comments